Rituximab in Chronic Lymphocytic Leukemia
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Danelle F, James , Thomas J. Kipps
- چاپ و سال / کشور: 2011
Description
Rituximab (Rituxan®; Biogen Idec, San Diego, CA, USA) is a human-mouse chimeric monoclonal antibody specific for CD20, a surface glycoprotein expressed on B lymphocytes. Administration of rituximab as a single agent to patients with chronic lymphocytic leukemia (CLL) has limited clinical activity, but generally does not eradicate leukemia from the marrow. However, when administered in combination with chemotherapy, rituximab can improve the survival of patients relative to those treated with chemotherapy alone. As a result of this, the US Food and Drug Administration approved the use of rituximab in previously untreated and previously treated CD20-positive CLL in combination with fludarabine monophosphate and cyclophosphamide. The results of clinical studies evaluating the activity of rituximab when used alone or in combination with other antileukemia agents for the treatment of this disease are reviewed here.
Adv Ther (2011) 28(7):534-554. DOI 10.1007/s12325-011-0032- Received: March 14, 2011 / Published online: June 20, 2011
